Expanded Access Policy

Ariceum is dedicated to designing and developing novel targeted radiopharmaceuticals that visualize and treat cancer. We work closely with leaders in all stages of clinical development, including researchers, regulatory authorities, and physicians, to efficiently attain regulatory approvals. Enrolment in our clinical trials is a crucial element of this process.

“Expanded Access” or “Compassionate Use” is a framework regulated by the FDA* to offer access to an investigational product to a patient with a serious disease or condition who is otherwise unable to enroll in a clinical trial or receive comparable and/or satisfactory alternative therapies.

At this stage in our development, Ariceum Therapeutics does not have an Expanded Access program in place. Ariceum may revise this policy at any time and will publish any changes accordingly. Patients should consult a physician for any specific questions. Physicians may contact Ariceum via clinical@ariceum-therapeutics.com.

*pursuant to Section 3032 of the 21st Century Cures Act and section 561 of the United States Food, Drug, and Cosmetics Act, as amended.